The 85th Scientific Sessions of the American Diabetes Association (ADA 2025)

Inhaled insulin appears to be equally efficacious and safe as the injected rapid-acting insulin analogue in children and adolescents with diabetes, according to data from the INHALE-1 study.

For adults with early type 2 diabetes (T2D) not adequately controlled by diet and exercise alone, treatment with the investigational small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron yields significant reductions in glycated haemoglobin levels, according to data from the phase III ACHIEVE-1 trial.

Once-a-week treatment with ecnoglutide demonstrates superiority over placebo, with sustained reductions in body weight and improvements in cardiometabolic indexes among adults with overweight or obesity, reports a study presented at ADA 2025.

Replacing diet beverages with water over 18 months leads to greater weight loss, improved glycaemic control, and higher diabetes remission in women with type 2 diabetes (T2D) and overweight or obesity. The benefits were sustained throughout the 18-month trial.

In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).